Eugene Kim

Eugene Kim

Auto-generated profile, based on publicly available information

Eugene Kim

Northwestern University Feinberg School of Medicine, Chicago, IL

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2022 in The Oncologist
Verified
Journal Article
Open access
PDF file
CKCyra Y Kang
Cyra Y Kang
SDSamantha E Duarte
Samantha E Duarte
HKHye Sung Kim
Hye Sung Kim
EKEugene Kim
Eugene Kim
JPJonghanne Park
Jonghanne Park
YCYoung Kwang Chae
Young Kwang Chae
The recent, rapid advances in immuno-oncology have revolutionized cancer treatment and spurred further research into tumor biology. Yet, cancer patients respond variably to immunotherapy despite mounting evidence to support its efficacy. Current methods for predicting immunotherapy response are unreliable, as these tests cannot fully account for tumor heterogeneity and microenvironment. An improved method for predicting response to immunotherapy is needed. Recent studies have proposed radiomics—the process of converting medical images into quantitative data (features) that can be processed using machine learning algorithms to identify complex patterns and trends—for predicting response to immunotherapy. Because patients undergo numerous imaging procedures throughout the course of the disease, there exists a wealth of radiological imaging data available for training radiomics models. And because radiomic features reflect cancer biology, such as tumor heterogeneity and microenvironment, these models have enormous potential to predict immunotherapy response more accurately than current methods. Models trained on preexisting biomarkers and/or clinical outcomes have demonstrated potential to improve patient stratification and treatment outcomes. In this review, we discuss current applications of radiomics in oncology, followed by a discussion on recent studies that use radiomics to predict immunotherapy response and toxicity.

26 February 2019 in Current Opinion in Behavioral Sciences
Verified
Journal Article
Closed access
SOSebastian Otto-Meyer
Sebastian Otto-Meyer
JLJan Lumibao
Jan Lumibao
EKEugene Kim
Eugene Kim
ELErik Ladomersky
Erik Ladomersky
LZLijie Zhai
Lijie Zhai
DWDerek Alan Wainwright
Derek Alan Wainwright

18 November 2024 in British Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
EKEugene Kim
Eugene Kim
MSMagdalena Stec
Magdalena Stec
NSNoreen Shaikh
Noreen Shaikh
JHJonathan Huang
Jonathan Huang
HRHantamalala Ralay Ranaivo
Hantamalala Ralay Ranaivo
RMRebecca Mets-Halgrimson
Rebecca Mets-Halgrimson
Background Remote learning during the COVID-19 pandemic caused behavioural changes such as increased screen time and decreased outdoor time. This study aimed to investigate myopia progression in children during the COVID-19 pandemic. Methods This was a retrospective observational study performed among 2064 patients ages 2–17 with cycloplegic refractions in the months of January 2019–March 2021 at a tertiary children’s hospital. Exclusion criteria were a medical history of relevant connective tissue diseases, myopia control treatment, pseudophakia and aphakia. Results The overall cohort (n=2064) had a mean spherical equivalent (SE) of 0.12±3.70 D in 2019, −0.07±3.95 D in 2020 and −0.49±3.85 D in 2021. The change in mean SE (0.42 D) from 2020 to 2021 was 2.2 times greater than the change (0.19 D) from 2019 to 2020 at baseline. In the cohort of return patients, there was a significant difference in myopic shift between years (F-ratio=14.4, p<0.00001), and a significant change from 2020 to 2021 (p=0.00008) but not from 2019 to 2020. When observing the prevalence of myopia grouped by age, 8-year-old and 17-year-old patients had the greatest increase compared with baseline. When grouped by refractive error, low myopia children (−0.5 D to −3.00 D) displayed the greatest change in mean SE 2020–2021. Conclusions There was a substantial increase in myopia progression for children in the Chicagoland area after the period of COVID-19 changes. The behavioural changes of home confinement and online learning during the pandemic may explain these findings.

1 November 2021 in JCO Precision Oncology
Verified
Journal Article
Closed access
WBWilliam Han Bae
William Han Bae
JHJin Young Hwang
Jin Young Hwang
WHWon Kyung Hur
Won Kyung Hur
JCJaeyoun Choi
Jaeyoun Choi
MNMyungwoo Nam
Myungwoo Nam
YCYoung Kwang Chae
Young Kwang Chae

14 April 2024 in medRxiv
Verified
Preprint
Open access
PDF file
EKEugene Kim
Eugene Kim
SDSamantha E Duarte
Samantha E Duarte
EYEmma Yu
Emma Yu
IHIlene Hong
Ilene Hong
GLGrace Lee
Grace Lee
YCYoung Kwang Chae
Young Kwang Chae
Introduction/Background: Genetic variants beyond FDA-approved drug targets are often identified in non-small cell lung cancer (NSCLC) patients. Although the performances of in silico tools in predicting variant pathogenicity have been analyzed in previous studies, they have not been analyzed for actionable targets of FDA-approved therapies for NSCLC. The aim of this study is to compare the performance of commonly used in silico tools in classifying the pathogenicity of actionable variants in NSCLC. Materials and Methods: We evaluated the performance of the following in silico tools: Polyphen-2 (HumDiv, HumVar), Align-GVGD, MutationTaster2021, CADD, CONDEL, and REVEL. A curated set of targetable NSCLC missense variants (n=236) was used. The overall accuracy, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and Matthews correlation coefficient (MCC) of each in silico tool was determined. Results: The most recently released MutationTaster2021 demonstrated the highest performance in terms of accuracy, specificity, PPV, and MCC, but was outperformed by CADD for both sensitivity and NPV. Although some tools demonstrated high sensitivities, all tools except MutationTaster2021 displayed markedly low overall specificities, as low as 23%. Conclusion: The collective results indicate that the evaluated in silico tools can provide guidance in predicting the pathogenicity of NSCLC missense variants, but are not fully reliable. The tools analyzed in this study could be acceptable to rule out pathogenicity in variants given their higher sensitivities, but are limited when it comes to identifying pathogenicity in variants due to low specificities. Highlights: MutationTaster2021 demonstrated the highest overall performance CADD demonstrated the highest sensitivity (99.19%) and NPV (96.55%). All tools but MutationTaster2021 demonstrated low specificities, as low as 23% An individual predictor outperformed 3 meta predictors Performance variability suggests caution when using in silico tools in the clinic

1 July 2021 in Cancer Research
Verified
Journal Article
Closed access
WHWon Kyung Hur
Won Kyung Hur
JHJin Young Hwang
Jin Young Hwang
LKLeeseul Kim
Leeseul Kim
MNMyungwoo Nam
Myungwoo Nam
WBWilliam H. Bae
William H. Bae
YCYoung Kwang Chae
Young Kwang Chae
Background: Apart from its role in ovarian cancer progression, epithelial-mesenchymal transition (EMT) can promote chemotherapy resistance. We aimed to analyze how the EMT score would affect the tumor microenvironment in ovarian cancer. Methods: cBioportal was queried to obtain The Cancer Genome Atlas (TCGA) data for the serous ovarian cancer (SOC) cohort (TCGA, 585 patients). The neoantigen prediction data was derived from the CloudNeo pipeline using TCGA mutation calling. EMT scores were calculated by subtracting the average RNA-seq z-scores of three epithelial marker genes from the average RNA-seq z-scores of 13 mesenchymal marker genes as described in the previous study. Patient samples were grouped as either EMT-high (highest 1/3) or EMT-low (lowest 1/3). CIBERSORT was applied to predict the tumor-infiltrating immune cells. Results: Among the 585 SOC patients, only 256 patients had mutation data available for our analysis. The EMT-low group had a significantly higher mutation count (p value=0.0004) and cytolytic score (p value=0.032) than the EMT-high group. In addition, the EMT-low samples were associated with improved overall survival in SOC patients (HR, 0.55; 95% CI, 0.39-0.78; P < 0.001). The median survival of EMT-low was 57.40, and EMT-high was 41.06 months. Neoantigen counts and PD-L1 express level tended to be higher in the EMT-high group although failed to show statistical significance. The immune cell infiltration rates were not different between both groups. Conclusions: Our study is the first to describe the association between the EMT potential, neoantigen counts, and cytolytic scores in SOC. In our analyses, tumors with low EMT potential had a significantly higher neoantigen burden and higher cytolytic scores, suggesting that tumors with low EMT potentials tend to be more immunogenic. Further studies are warranted to explore the utility of EMT scores as biomarkers to predict the treatment response to immunotherapy in SOC. Citation Format: Won Kyung Hur, Jin Young Hwang, Leeseul Kim, Myungwoo Nam, William H. Bae, Yoonhee Choi, Yeun Ho Lee, Heayoon S. Cho, Emma Yu, Chan Mi Jung, William Cheng, Eugene Kim, Christmann Low, Victor Wang, Jeff Chuang, Young Kwang Chae. The neoantigen and immune landscape of epithelial mesenchymal transition (EMT) low and high score serous ovarian cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 626.